TransGenic Group

TransGenic Group Accounts Payable

The Accounts Payable of TransGenic Group (2342.T) as of Nov 11, 2026 is 415.62 M JPY. In the previous year, Accounts Payable was 413.46 M JPY — a change of 0.52% (higher).

Accounts Payable

415.62 MJPY

YoY

0.52%

Last updated:

Accounts Payable of TransGenic Group is 2026 415.62 M JPY. Accounts Payable of TransGenic Group was 2025 413.46 M JPY. It decreases by 0.52% higher compared to the previous year.

The TransGenic Group Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2019
53.05 M JPY
Jan 1, 2020
305.37 M JPY
Jan 1, 2021
340.14 M JPY
Jan 1, 2022
256.01 M JPY
Jan 1, 2023
408.74 M JPY
Jan 1, 2024
276.14 M JPY
Jan 1, 2025
413.46 M JPY
Jan 1, 2026
415.62 M JPY
The TransGenic Group Accounts Payable history
YEARAccounts PayableYoY
415.62 MJPY+0.52%
413.46 MJPY+49.73%
276.14 MJPY-32.44%
408.74 MJPY+59.66%
256.01 MJPY-24.73%
340.14 MJPY+11.39%
305.37 MJPY+475.68%
53.05 MJPY+18.11%
44.91 MJPY+966.24%
4.21 MJPY-82.88%
24.61 MJPY-88.22%
208.97 MJPY+24.93%
167.28 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Accounts Payable of TransGenic Group is 415.62 M JPY in 2026.

Accounts Payable of TransGenic Group changed from 413.46 M JPY to 415.62 M JPY, representing a 0.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TransGenic Group

All Key Metrics — TransGenic Group